Statements (86)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:activities |
inhibits specific enzymes
antibiotic resistance modulation inhibits immune checkpoint proteins inhibits the activity of certain antibiotics inhibits beta-lactam antibiotics |
| gptkbp:advocates_for |
required
|
| gptkbp:analysis |
statistical analysis
|
| gptkbp:analyzes |
gptkb:Dr._John_Doe
|
| gptkbp:appointed_by |
oral medication
oral tablet |
| gptkbp:business_model |
obtained
|
| gptkbp:clinical_trial |
gptkb:United_States
gptkb:theorem 2021-01-01 ongoing 2023-12-31 Phase 1 early phase NCTXXXXXXX |
| gptkbp:collaborations |
various clinical research organizations
|
| gptkbp:collection |
questionnaires
|
| gptkbp:committee |
established
|
| gptkbp:criteria |
age 18-65
history of gastrointestinal disease |
| gptkbp:developed_by |
gptkb:Synthetic_Biologics
Syndax Pharmaceuticals |
| gptkbp:developer |
gptkb:Synthetic_Biologics
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:events |
6 months
|
| gptkbp:field_of_study |
antibiotic development
|
| gptkbp:frequency |
once daily
|
| https://www.w3.org/2000/01/rdf-schema#label |
SYN-004
|
| gptkbp:indication |
solid tumors
prevention of C. difficile infection prevention of antibiotic-associated diarrhea antibiotic-associated diarrhea |
| gptkbp:ingredients |
SYN-004 compound
|
| gptkbp:invention |
patented
|
| gptkbp:is_protected_by |
parallel assignment
|
| gptkbp:is_tested_for |
Phase 1
clinical trials Phase 1 trial |
| gptkbp:is_used_for |
preventing diarrhea
|
| gptkbp:location |
multiple sites in the US
|
| gptkbp:manager |
oral
intravenous |
| gptkbp:members |
placebo group
|
| gptkbp:participants |
gptkb:television_series
safety and tolerability efficacy against C. difficile |
| gptkbp:population |
healthy adults
|
| gptkbp:products |
gptkb:SYN-004
|
| gptkbp:project |
Phase 1
clinical trials |
| gptkbp:publishes |
results to be published
|
| gptkbp:receives_funding_from |
private investment
|
| gptkbp:recorded_by |
randomized
|
| gptkbp:regulatory_compliance |
investigational new drug
|
| gptkbp:research |
completed
pending randomized controlled trial |
| gptkbp:safety_features |
ongoing
|
| gptkbp:side_effect |
headache
nausea abdominal pain diarrhea |
| gptkbp:social_structure |
gptkb:Cloud_Computing_Service
|
| gptkbp:sponsor |
gptkb:Synthetic_Biologics,_Inc.
|
| gptkbp:status |
gptkb:legal_case
under investigation investigational investigational drug |
| gptkbp:targets |
gptkb:healthcare_organization
gptkb:C._difficile gptkb:Clostridium_difficile_infection gut microbiome |
| gptkbp:treatment |
SYN-004 group
|
| gptkbp:type |
gptkb:Cloud_Computing_Service
oral enzyme |
| gptkbp:vision |
double-blind
|
| gptkbp:year |
2023-12-31
2023-06-30 |
| gptkbp:bfsParent |
gptkb:Syntimmune
|
| gptkbp:bfsLayer |
5
|